A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection In Vivo

Area of Science:

• Immunology
• Pharmacology
• Transplantation

Background:

• The mixed lymphocyte reaction (MLR) is a key in vitro model for predicting in vivo graft rejection.
• Cannabinoid receptor 2 (CB2) selective agonists have demonstrated immunosuppressive properties in vitro.
• Previous studies indicated that O-1966, a CB2 agonist, inhibits T-cell proliferation and modulates immune cell populations.

Purpose of the Study:

• To evaluate the in vivo efficacy of the CB2 selective agonist O-1966 in prolonging skin graft survival.
• To investigate the immunological mechanisms underlying O-1966's immunosuppressive effects in a murine skin transplantation model.

Main Methods:

• C57BL/6 mice received skin grafts from C3HeB/FeJ donors.
• O-1966 was administered intraperitoneally starting 1 hour pre-operation and continued every other day for 14 days.
• Graft survival was monitored, and spleen weights and immune cell populations (including regulatory T cells) were analyzed via flow cytometry.

Main Results:

• O-1966 treatment significantly prolonged mean skin graft survival from 9 to 11 days.
• Treated mice exhibited smaller spleen weights and a nearly 3-fold increase in CD25+Foxp3+ regulatory T cells (Tregs).
• Ex vivo MLR assays showed suppressed proliferative responses of spleen cells from O-1966 treated mice.

Conclusions:

• CB2 selective agonists, exemplified by O-1966, represent a novel therapeutic class for enhancing allograft survival.
• O-1966's mechanism involves the induction of Tregs and suppression of T-cell alloreactivity.
• These findings support the potential of CB2 agonists in clinical organ transplantation to prevent rejection.